These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. Jankovic J; Stacy M CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819 [TBL] [Abstract][Full Text] [Related]
5. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease. Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377 [TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Kulisevsky J; Pagonabarraga J Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541 [TBL] [Abstract][Full Text] [Related]
7. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817 [TBL] [Abstract][Full Text] [Related]
8. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial. Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE; JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574 [TBL] [Abstract][Full Text] [Related]
12. Dopaminergic agonists in Parkinson's disease. Alonso Cánovas A; Luquin Piudo R; García Ruiz-Espiga P; Burguera JA; Campos Arillo V; Castro A; Linazasoro G; López Del Val J; Vela L; Martínez Castrillo JC Neurologia; 2014 May; 29(4):230-41. PubMed ID: 21724302 [TBL] [Abstract][Full Text] [Related]
13. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. Pahwa R J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613 [TBL] [Abstract][Full Text] [Related]
14. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Deleu D; Northway MG; Hanssens Y Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145 [TBL] [Abstract][Full Text] [Related]
16. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Lees A Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677 [TBL] [Abstract][Full Text] [Related]